Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

Benzinga Newsdesk www.benzinga.com Positive 78.7%

Neg 0% Neu 0% Pos 78.7%

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $4.2 to $5.5.